Corvus Pharmaceuticals | 4:持股变动声明-高管 MILLER RICHARD A MD
Corvus Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Samlyn Capital, LLC(9.99%),Samlyn, LP(9.99%)等
Corvus Pharmaceuticals | SC 13G:超过5%持股股东披露文件-Point72 Asset Management, L.P.(9.9%),Point72 Capital Advisors, Inc.(9.9%)等
Corvus Pharmaceuticals | 4:持股变动声明-董事 Thompson Peter A.
Corvus Pharmaceuticals | 4:持股变动声明-董事 ORBIMED ADVISORS LLC
Corvus Pharmaceuticals | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Advisors LLC(11.1%),OrbiMed Capital GP V LLC(11.1%)
Corvus Pharmaceuticals | 10-Q:季度报表
Corvus Pharmaceuticals | S-8:员工福利计划证券登记
Corvus Pharmaceuticals | 4:持股变动声明-高管 Jones William Benton
Corvus Pharmaceuticals | 4:持股变动声明-高管 MILLER RICHARD A MD
Corvus Pharmaceuticals | 8-K:重大事件
Corvus Pharmaceuticals | 8-K:Corvus Pharmicals提供最新业务并报告2024年第一季度财务业绩
Corvus Pharmaceuticals | 424B5:募资说明书
Corvus Pharmaceuticals | 8-K:重大事件
Corvus Pharmaceuticals | DEFA14A:其他
Corvus Pharmaceuticals | DEF 14A:股东委托书决议
Corvus Pharmaceuticals | 10-K:年度报表
Corvus Pharmaceuticals | 8-K:Corvus Pharmicals提供最新业务并报告2023年第四季度和全年财务业绩
Corvus Pharmaceuticals | 4:持股变动声明-高管 Arcara Jeffrey
Corvus Pharmaceuticals | SC 13G:超过5%持股股东披露文件-Samlyn Capital, LLC(5.1%),Samlyn, LP(5.1%)等
暂无数据